Literature DB >> 26537478

Timing of breakfast does not influence therapeutic efficacy of liquid levothyroxine formulation.

Silvia Morelli1,2, Gianpaolo Reboldi1, Sonia Moretti1,2, Elisa Menicali1,2, Nicola Avenia2,3, Efisio Puxeddu4,5.   

Abstract

Oral levothyroxine (L-T4) is the mainstay of hypothyroidism treatment. Many factors may influence its absorption, including the timing of administration. Objective of the study is to demonstrate the therapeutic equivalence of administering liquid L-T4 with breakfast or 10 min before breakfast. This was a pilot study conducted with a crossover design AB/BA where A stays for L-T4 with breakfast and B for L-T4 10 min before breakfast. A post hoc analysis was conducted to compare L-T4 administered at breakfast or 10 min before breakfast with L-T4 administered 30 min before breakfast. Sixty-one hypothyroid patients were enrolled and assigned to one of the two treatment sequences. All patients were evaluated for TSH levels at the end of each period. Fifty-nine patients completed the study. The mean thyrotropin concentration was 1.52 ± 0.73 µU/ml when L-T4 was administered with breakfast and 1.46 ± 0.81 µU/ml when it was taken 10 min before breakfast, without clinically and statistically significant differences (P = 0.59), regardless of treatment sequence and period. The mean thyrotropin concentration was 1.54 ± 0.9 µU/ml when L-T4 was administered at 0-10 min intervals before breakfast and 1.25 ± 0.7 µU/ml when it was taken 30 min before breakfast (ratio = 1.23, within our definition of equivalence set at 0.8-1.25). There is therapeutic equivalence between liquid L-T4 administration at breakfast or 10 min before breakfast. We can also hypothesize that there are no clinically relevant differences between liquid L-T4 administration 30 min before breakfast or at shorter intervals.

Entities:  

Keywords:  Hypothyroidism; Levothyroxine; Oral solution; Replacement therapy; TSH; Therapeutic equivalence

Mesh:

Substances:

Year:  2015        PMID: 26537478     DOI: 10.1007/s12020-015-0788-2

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  40 in total

1.  The magnitude of increased levothyroxine requirements in hypothyroid pregnant women depends upon the etiology of the hypothyroidism.

Authors:  Jennifer A Loh; Leonard Wartofsky; Jacqueline Jonklaas; Kenneth D Burman
Journal:  Thyroid       Date:  2009-03       Impact factor: 6.568

2.  Thyroxine treatment: absorption, malabsorption, and novel therapeutic approaches.

Authors:  Marco Centanni
Journal:  Endocrine       Date:  2012-10-25       Impact factor: 3.633

3.  A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations.

Authors:  Roberto Vita; Giovanna Saraceno; Francesco Trimarchi; Salvatore Benvenga
Journal:  Endocrine       Date:  2012-08-30       Impact factor: 3.633

4.  Variations in adequate levothyroxine replacement therapy in patients with different causes of hypothyroidism.

Authors:  M B Gordon; M S Gordon
Journal:  Endocr Pract       Date:  1999 Sep-Oct       Impact factor: 3.443

5.  Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients.

Authors:  Massimo Torlontano; Cosimo Durante; Isabella Torrente; Umberto Crocetti; Giovanni Augello; Giuseppe Ronga; Teresa Montesano; Laura Travascio; Antonella Verrienti; Rocco Bruno; Stefano Santini; Palmina D'Arcangelo; Bruno Dallapiccola; Sebastiano Filetti; Vincenzo Trischitta
Journal:  J Clin Endocrinol Metab       Date:  2007-12-11       Impact factor: 5.958

6.  Aging and the thyroid. Decreased requirement for thyroid hormone in older hypothyroid patients.

Authors:  C T Sawin; T Herman; M E Molitch; M H London; S M Kramer
Journal:  Am J Med       Date:  1983-08       Impact factor: 4.965

Review 7.  The administration of L-thyroxine as soft gel capsule or liquid solution.

Authors:  Roberto Vita; Poupak Fallahi; Alessandro Antonelli; Salvatore Benvenga
Journal:  Expert Opin Drug Deliv       Date:  2014-06-04       Impact factor: 6.648

Review 8.  [Oral thyroxine treatment: towards an individually tailored dose].

Authors:  Marco Centanni; Antonella Franchi; Maria Giulia Santaguida; Camilla Virili; Serena Nardo; Lucilla Gargano
Journal:  Recenti Prog Med       Date:  2007-09

9.  Thr92Ala polymorphism in the type 2 deiodinase is not associated with T4 dose in athyroid patients or patients with Hashimoto thyroiditis.

Authors:  K A Heemstra; H C Hoftijzer; W M van der Deure; R P Peeters; E Fliers; B C Appelhof; W M Wiersinga; E P M Corssmit; T J Visser; J W A Smit
Journal:  Clin Endocrinol (Oxf)       Date:  2008-11-07       Impact factor: 3.478

10.  Timing of levothyroxine administration affects serum thyrotropin concentration.

Authors:  Thien-Giang Bach-Huynh; Bindu Nayak; Jennifer Loh; Steven Soldin; Jacqueline Jonklaas
Journal:  J Clin Endocrinol Metab       Date:  2009-07-07       Impact factor: 5.958

View more
  16 in total

Review 1.  Novel thyroxine formulations: a further step toward precision medicine.

Authors:  Camilla Virili; Pierpaolo Trimboli; Marco Centanni
Journal:  Endocrine       Date:  2019-10-15       Impact factor: 3.633

2.  Comparative study between the effects of replacement therapy with liquid and tablet formulations of levothyroxine on mood states, self-perceived psychological well-being and thyroid hormone profile in recently thyroidectomized patients.

Authors:  Celestino Pio Lombardi; Raffaella Bocale; Angelina Barini; Antonella Barini; Annamaria D'Amore; Mauro Boscherini; Rocco Bellantone
Journal:  Endocrine       Date:  2016-07-07       Impact factor: 3.633

3.  Treatment of hypothyroidism: all that glitters is gold?

Authors:  Anna Maria Formenti; Gherardo Mazziotti; Raffaele Giubbini; Andrea Giustina
Journal:  Endocrine       Date:  2016-02-29       Impact factor: 3.633

4.  Patients with lactose intolerance absorb liquid levothyroxine better than tablet levothyroxine.

Authors:  Poupak Fallahi; Silvia Martina Ferrari; Santino Marchi; Nicola De Bortoli; Ilaria Ruffilli; Alessandro Antonelli
Journal:  Endocrine       Date:  2016-08-30       Impact factor: 3.633

Review 5.  Liquid and softgel levothyroxine use in clinical practice: state of the art.

Authors:  Camilla Virili; Pierpaolo Trimboli; Francesco Romanelli; Marco Centanni
Journal:  Endocrine       Date:  2016-07-29       Impact factor: 3.633

Review 6.  Liquid L-thyroxine versus tablet L-thyroxine in patients on L- thyroxine replacement or suppressive therapy: a meta-analysis.

Authors:  Irakoze Laurent; Siying Tang; Manirakiza Astère; Kan Ran Wang; Shuhua Deng; Ling Xiao; Qi Fu Li
Journal:  Endocrine       Date:  2018-03-23       Impact factor: 3.633

7.  Tablet and oral liquid L-thyroxine formulation in the treatment of naïve hypothyroid patients with Helicobacter pylori infection.

Authors:  Danilo Ribichini; Giulia Fiorini; Andrea Repaci; Valentina Castelli; Luigi Gatta; Dino Vaira; Renato Pasquali
Journal:  Endocrine       Date:  2016-11-15       Impact factor: 3.633

8.  Levothyroxine Therapy: Changes of TSH Levels by Switching Patients from Tablet to Liquid Formulation. A Systematic Review and Meta-Analysis.

Authors:  Camilla Virili; Luca Giovanella; Poupak Fallahi; Alessandro Antonelli; Maria Giulia Santaguida; Marco Centanni; Pierpaolo Trimboli
Journal:  Front Endocrinol (Lausanne)       Date:  2018-01-26       Impact factor: 5.555

9.  TSH Variability of Patients Affected by Differentiated Thyroid Cancer Treated with Levothyroxine Liquid Solution or Tablet Form.

Authors:  Carlo Cappelli; Ilenia Pirola; Elena Gandossi; Claudio Casella; Davide Lombardi; Barbara Agosti; Fiorella Marini; Andrea Delbarba; Maurizio Castellano
Journal:  Int J Endocrinol       Date:  2017-05-09       Impact factor: 3.257

10.  Thyroid Hormone Profile in Patients Ingesting Soft Gel Capsule or Liquid Levothyroxine Formulations with Breakfast.

Authors:  Carlo Cappelli; Ilenia Pirola; Elena Gandossi; Alessandra Cristiano; Linda Daffini; Barbara Agosti; Claudio Casella; Maurizio Castellano
Journal:  Int J Endocrinol       Date:  2016-05-30       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.